UHL is proud to announce the launch of the UK’s first joint respiratory and thoracic NHS robotic bronchoscopy services outside of London.
Based at Glenfield Hospital, this cutting-edge technology aims to enhance early diagnosis and treatment of lung cancer, which remains one of the leading causes of cancer-related deaths in the UK. Lung cancer often has poor survival rates due to late diagnosis, when treatment options become more limited and less effective.
A new targeted lung cancer screening programme is set to begin in Leicestershire in 2025, aimed at people aged 55-74 who are at high risk of lung cancer, particularly current and former smokers. This screening will use a low-dose CT scan to detect lung nodules (small shadows in the lung) which may require a biopsy to determine if they are cancerous.
Over 70 per cent of lung cancer nodules are located in the outer regions of the lungs, making them difficult to reach with traditional biopsy methods. This can delay diagnosis and extend the time before patients can start treatment. The new robotic-assisted bronchoscopy system offers a more precise, minimally invasive way to biopsy lung nodules, streamlining the patient’s journey and reducing the need for multiple procedures. It also allows the team to mark smaller nodules which pose challenges in resecting them.
The ION robot by US company Intuitive, is an advanced system featuring a high-precision, ultra-thin bronchoscope, allowing doctors to navigate to hard-to-reach areas of the lung. A 3D map of the lungs is displayed on a screen to guide the doctor, similar to a satellite navigation system in your car, while integrating 3D CT scans during the procedure to ensure an accurate and effective biopsy. Looking ahead, this innovative technology may also allow for the treatment of early-stage lung cancer without the need for surgery.
Dr Rakesh K Panchal, Consultant Respiratory Physician and Clinical Lead for Interventional Pulmonology at UHL, said: "This robotic bronchoscopy service marks a significant step forward for our patients in Leicestershire and beyond. By using this state-of-the-art technology, we can offer more precise diagnosis, reduce delays, and ultimately improve patient outcomes. It’s a proud moment for the Trust and a testament to the collaborative work of our respiratory and thoracic surgery teams.”
Mr Apostolos Nakas, Consultant Thoracic Surgeon and Deputy Divisional Director, RRCV added: “This robotic technology, used in combination with our existing surgical robotic systems, offers newer ways of diagnosis and treatment for small nodules, including locating and resecting early lung cancer and secondary cancers, and fits in well with the Thoracic Surgical Robotic Surgical Strategy”.
The robotic bronchoscopy service will benefit not only Leicestershire residents, but also patients across the East and West Midlands, offering a faster, more efficient pathway for the diagnosis and treatment of suspected lung cancer.
